The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality - Zhang, C; Wu, Z; Li, J W (Int J Antimicrob Agents, 2020)
et al.